These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: An immunosensing device based on inhibition of mediator's faradaic process for early diagnosis of prostate cancer using bifunctional nanoplatform reinforced by carbon nanotube.
    Author: Farzin L, Sadjadi S, Shamsipur M, Sheibani S.
    Journal: J Pharm Biomed Anal; 2019 Aug 05; 172():259-267. PubMed ID: 31078062.
    Abstract:
    In this study, a simple and lable-free voltammetric immunosensor was successfully developed for the ultrasensitive detection of prostate specific antigen (PSA). To do this, multiwalled carbon nanotube (MWCNT)/L-histidine functionalized reduced graphene oxide (His-rGO) was demonstrated as a bifunctional nanoplatform for covalently attaching thionine redox indicator and anti-PSA antibody (Ab). The MWCNT enhanced electrical conductivity and facilitated the electron transfer between thionine and the glassy carbon electrode. While, the presence of anti-PSA antibody blocked the electron transfer of thionine and decreased redox signals. The principle response of proposed immunosensor was based on the selective interaction of PSA with thionine-NH2-GO-COOH-Ab. This selective interaction led to further decrease of response current of attached electrochemical probe. The liner calibration curve for tumor marker determination was 10 fg mL-1-20 ng mL-1 (R2 = 0.996). Under optimized conditions, the immunosensor was able to selectively detect PSA with a limit of detection (LOD) of 2.8 fg mL-1 at 3σ. The relative standard deviations (RSDs) for single-electrode repeatability and electrode-to-electrode reproducibility were less than 2.9% and 5.7% (n = 5), respectively. Furthermore, the as-proposed immunosensor showed excellent performance in detection of PSA in the human serum and saliva samples, which implies that the current strategy has a promising feature for the clinical assessment of tumor marker status in patients with prostate cancer.
    [Abstract] [Full Text] [Related] [New Search]